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Background
Cause and effect of dietary constituents on the genesis of
NCD epidemics (CVD, diabetes, etc) in the Western
developed and some developing countries has been diffi-
cult to unravel. It appears that inflammation is a key fac-
tor and that in its absence total cholesterol may have an
apparently neutral effect on arterial tissues and the myo-
cardium. The Mediterranean-style diet, combined with
physical exercise, resembles a notional Palaeolithic diet of
a pre-agricultural era in that the ratio of omega-3/omega-
6 unsaturated fatty acids is higher than in most Western
diets [1]. Furthermore, evidence suggests that this higher
ratio can beneficially change brain function and its inter-
action with gut, liver and heart and influence mind-body
interactions. This group, in collaboration with others,
seek to test the hypothesis, albeit for a 4y longitudinal
psychosomatic randomised placebo control vs. omega-3
intervention trial of 90 subjects, 30 each in adolescent,
adult and elderly groups of men and women in Poland,
that this higher ratio can not only favourably change the
rhythmic characteristics of blood pressure and heart rate,
but beneficially improve mental health. However, a 3m
feasibility study has been undertaken to test methods and
safety associated with the main protocol the underpin-
ning objective being that a return to the original balanced
(1:1) ratio of polyunsaturated fatty acids (PUFAs) and/or
to a corresponding 25% proportion of ω6 highly unsatu-
rated fatty acids (HUFAs) in plasma/ serum total lipids
(ω6:ω3 PUFAs = 1:1 and/or %ω6 in HUFAs = 25) can
possibly reduce the risk of developing chronic degenera-
tive diseases towards zero at the population level.
Materials and methods
Subjects (consented): 5 family-related members + 4 family
acquainted subjects were arranged in the three age groups.
Clinical (published elsewhere [2]): General medical exami-
nation with blood and urine tests; psychological health
assessment using Eysenck’s Personality Questionnaire
(Polish); body mass composition; ambulatory blood pres-
sure monitoring; blood lipids were the main methods.
Results
All subjects reported subjective mind and body health
improvements concerning cognition, concentration, com-
munication, breathing, general feeling, relief of dizziness
and pain confirmed by medical, biochemical and socio-
psychological analyses. In all three subgroups, prolonged
w-3 HUFA intake appears to maintain the new status, not
to further reduce it. The main results were: 1. Daily intake
of w-3 HUFA needed to reverse the Omega-6 Status from
75 to 50% (3.35g w-3 HUFA )/day) and then from 50 to
25% (3.35g w-3 HUFA/day) in the blood-tissue of a mod-
ern Western population was redefined; 2. Benefits of the
presence of a “blunter” (LIPISTASE) of inter-individual
genotypic variance were indicated; 3. A reduction in daily
intake of omega-6 fatty acids from plant and animal ori-
gins is probably needed to augment post-intervention to
reach the evolutionary selected blood/tissue ratio; 4. age
and gender, body composition, metabolic rate and lifestyle
did not substantially affect the linear relationship between
the change in w6S and omega-3 intervention dose. Safety
appears not to be an issue.
Conclusions
Pilot data supports, with amendments, the implementation
of the 4y longitudinal randomized placebo vs. omega-3
intervention trial.
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